Liquid biopsy is an emerging area of clinical research, particularly in the context of cancer. As a minimally invasive complementary or alternative approach to tissue biopsies, liquid biopsies are less risky, painful, and costly, and are increasingly being used to analyze biomarkers in liquid samples, such as blood. Recent advances in genomic technologies, such as digital PCR (dPCR) and next-generation sequencing (NGS), have enabled researchers to more comprehensively detect and study cancer-related mutations, even when they are very rare. With this panel of key opinion leaders in the liquid biopsy space, we dive deeper into the impact of genomics and genomics technologies on the current and future of liquid biopsy clinical research and cancer management. At Thermo Fisher Scientific we are committed to developing robust sample preparation solutions for cell-free nucleic acids and highly sensitive liquid biopsy assays utilizing both dPCR and targeted NGS to enable cancer driver identification, serial monitoring, and potential recurrence detection.
On-demand webinar Part 1: Enter event in auditorium to access
Discuss the features of digital PCR and its advantages in liquid biopsy research
Understand the ways dPCR can be used to support precision medicine research
Discuss the types of analytes used for dPCR analysis
Define the current state of dPCR for routine monitoring of cancer patients and future trends
For Research Use Only. Not for use in diagnostic procedures.
Webinars will be available for unlimited on-demand viewing after live event.
Labroots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.
Join us for an insightful webinar to discuss a holistic approach to testing for TB in a clinical setting. Tuberculosis remains a global health challenge and accurate, timely diagnosis is cri...
Personalized medicine promises to significantly improve patient outcomes, but achieving this requires a deep understanding of human health and disease mechanisms at the molecular level. The...
CAR-T translational research demands precise, reproducible, and scalable flow cytometry workflows. Manual centrifugation and antibody preparation steps remain major sources of variability an...
Bloodstream infections (BSIs) remain a critical challenge in clinical care, where every hour of delay in diagnosis can significantly impact patient outcomes. This webinar explores findings f...
Lipid nanoparticles (LNPs) have become the gold standard in non-viral gene delivery technologies, exemplified by the approval of the LNP messenger RNA (mRNA) vaccines against SARS-CoV-2. Sin...
Cell line development (CLD) is often a critical bottleneck in biopharmaceutical production, often requiring labor-intensive workflows and multiple sequential screening steps that extend time...
Loading Comments...
Please update your information
Certificate of Participation
Thank you for choosing Labroots. Please note that a Certificate of Participation does NOT count towards Continuing Education Credits.